What's new

Orphan designation: small-interfering RNA against soluble fms-like tyrosine kinase-1 e15a mRNA, small-interfering RNA against soluble fms-like tyrosine kinase-1 i13 mRNA Treatment of pre-eclampsia, 16/04/2025 Positive

Orphan designation: small-interfering RNA against soluble fms-like tyrosine kinase-1 e15a mRNA, small-interfering RNA against soluble fms-like tyrosine kinase-1 i13 mRNA Treatment of pre-eclampsia, 16/04/2025 Positive

Jun 5, 2025 - 15:00
 0
Orphan designation: small-interfering RNA against soluble fms-like tyrosine kinase-1 e15a mRNA, small-interfering RNA against soluble fms-like tyrosine kinase-1 i13 mRNA Treatment of pre-eclampsia, 16/04/2025 Positive
Orphan designation: small-interfering RNA against soluble fms-like tyrosine kinase-1 e15a mRNA, small-interfering RNA against soluble fms-like tyrosine kinase-1 i13 mRNA Treatment of pre-eclampsia, 16/04/2025 Positive
Read More

Tags:

Previous Article

Orphan designation: autologous T lymphocyte-enriched population of cells transdu...

Next Article

Orphan designation: humanised IgG1 monoclonal antibody against muscle specific k...

Related Posts

Human medicines European public assessment report (EPAR): Bylvay, odevixibat, Date of authorisation: 16/07/2021, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR...

Jun 6, 2025  0

Human medicines European public assessment report (EPAR): Deqsiga, human normal immunoglobulin, Date of authorisation: 02/05/2025, Status: Authorised

Human medicines European public assessment report (EPAR...

May 16, 2025  0

PSUSA/00010355/202409

PSUSA/00010355/202409

May 27, 2025  0